短腸症候群市場：按藥物類別、分銷渠道-俄烏衝突和高通脹-2023-2030年全球預測

預計2023年全球短腸症候群市場將達到81823萬美元，複合年增長率為18.95%，大幅增長，2030年將達到278872萬美元。

FPNV定位矩陣

FPNV 定位矩陣對於評估全球短腸症候群市場至關重要。 通過檢查業務戰略和產品滿意度的關鍵指標，我們對供應商進行全面評估，使您能夠根據您的具體需求做出明智的決策。 這種高級分析將供應商分為四個像限，並取得了不同程度的成功：前沿 (F)、探路者 (P)、利基 (N) 和重要 (V)。

市場份額分析

市場份額分析可以深入了解供應商在特定市場區域的當前狀態。 比較供應商對整體收入、客戶群和其他關鍵指標的貢獻，可以幫助公司更好地了解他們在爭奪市場份額時的表現以及面臨的情況。 該分析還揭示了特定行業的競爭程度、積累和分散的優勢以及研究基準年的合併特徵。

本報告提供了以下幾點見解：

1. 市場滲透率：提供有關主要公司所服務的市場的全面資訊。

2. 市場開發：提供有關利潤豐厚的新興市場的詳細資訊，並分析其在成熟市場領域的滲透率。

3. 市場多元化：提供有關新產品發布、未開發地區、最新開發和投資的詳細資訊。

4.市場趨勢：全面了解俄羅斯-烏克蘭衝突和高通脹。

5.競爭評估和資訊：對主要公司的市場份額、戰略、產品、認證、監管狀況、專利狀況、製造能力進行綜合評估。

6. 產品開發和創新：提供對未來技術、研發活動和突破性產品開發的見解。

此報告回答了以下問題：

1.短腸症候群的全球市場規模和預測是多少？

2.在預測期內，COVID-19 對全球短腸症候群市場的影響有哪些障礙和影響？

3.在預測期內，全球短腸症候群市場應投資哪些產品/細分市場/應用/領域？

4.你們在全球短腸症候群市場的競爭策略是什麼？

5.全球短腸症候群市場的技術趨勢和監管框架是什麼？

6.全球短腸症候群市場主要供應商的市場份額是多少？

7.什麼形式和戰略舉措適合進入全球短腸症候群市場？

目錄

第 1 章前言

第 2 章研究方法

第 3 章執行摘要

第 4 章市場概述

第 5 章市場洞察

• 市場動態
  • 促進因素
    • 短腸症候群患病率增加和宣傳計劃
    • 加大力度推出有效的治療方法
  • 抑制因素
    • 缺乏經批准的治療方案和藥物相關的不良並發症
  • 機會
    • 短腸症候群藥物開發尚處於早期階段
    • 公私合作鼓勵製藥公司開發治療短腸症候群的新孤兒藥
  • 課題
    • 初始診斷和高級選項的可用性有限
• 市場趨勢
• 新冠肺炎 (COVID-19) 的累積影響
• 俄羅斯-烏克蘭衝突的累積影響
• 高通脹的累積影響
• 波特五力分析
• 價值鍊和關鍵路徑分析
• 監管框架
• 客戶定制

第 6 章按藥物類別劃分的短腸症候群市場

• GLP-2
• 谷氨□胺
• 生長激素

第 7 章短腸症候群市場：按分銷渠道劃分

• 醫院藥房
• 在線銷售
• 零售藥店

第 8 章北美和南美短腸症候群市場

• 阿根廷
• 巴西
• 加拿大
• 墨西哥
• 美國

第 9 章亞太地區短腸症候群市場

• 澳大利亞
• 中國
• 印度
• 印度尼西亞
• 日本
• 馬來西亞
• 菲律賓
• 新加坡
• 韓國
• 台灣
• 泰國
• 越南

第 10 章歐洲、中東和非洲的短腸症候群市場

• 丹麥
• 埃及
• 芬蘭
• 法國
• 德國
• 以色列
• 意大利
• 荷蘭
• 尼日利亞
• 挪威
• 波蘭
• 卡塔爾
• 俄羅斯
• 沙特阿拉伯
• 南非
• 西班牙
• 瑞典
• 瑞士
• 土耳其
• 阿拉伯聯合酋長國
• 英國

第 11 章競爭態勢

• FPNV定位矩陣
• 市場份額分析：主要公司
• 競爭情景分析：主要公司

第 12 章上市公司名單

第 13 章附錄

• 討論指南
• 關於許可證和價格

The Global Short Bowel Syndrome Market is forecasted to grow significantly, with a projected USD 818.23 million in 2023 at a CAGR of 18.95% and expected to reach a staggering USD 2,788.72 million by 2030.

The the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Short Bowel Syndrome Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.

Market Segmentation & Coverage:

This research report categorizes the Global Short Bowel Syndrome Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Drug Class, market is studied across GLP-2, Glutamine, and Growth Hormone. The Glutamine commanded largest market share of 39.26% in 2022, followed by GLP-2.

Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Sales, and Retail Pharmacies. The Retail Pharmacies commanded largest market share of 52.51% in 2022, followed by Hospital Pharmacies.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Europe, Middle East & Africa commanded largest market share of 35.38% in 2022, followed by Americas.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Global Short Bowel Syndrome Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Market Trends: Provides comprehensive understanding of the the Russia-Ukraine Conflict, and the High Inflation

5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Short Bowel Syndrome Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Short Bowel Syndrome Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Short Bowel Syndrome Market?

4. What is the competitive strategic window for opportunities in the Global Short Bowel Syndrome Market?

5. What are the technology trends and regulatory frameworks in the Global Short Bowel Syndrome Market?

6. What is the market share of the leading vendors in the Global Short Bowel Syndrome Market?

7. What modes and strategic moves are considered suitable for entering the Global Short Bowel Syndrome Market?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Limitations
• 1.7. Assumptions
• 1.8. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

• 4.1. Introduction
• 4.2. Short Bowel Syndrome Market, by Drug Class, 2022 vs 2030
• 4.3. Short Bowel Syndrome Market, by Distribution Channel, 2022 vs 2030
• 4.4. Short Bowel Syndrome Market, by Region, 2022 vs 2030

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increased Prevalence of Short Bowel Syndrome and Awareness Programs
    • 5.1.1.2. Rising Efforts in the Launch of Effective Treatments
  • 5.1.2. Restraints
    • 5.1.2.1. Lack of Approved Treatment Options and Associated Adverse Complications with Drugs
  • 5.1.3. Opportunities
    • 5.1.3.1. Development of Short Bowel Syndrome Drugs is at a Nascent Stage
    • 5.1.3.2. Public-Private Partnerships are Encouraging Pharmaceutical Companies to Develop New Orphan Drugs for Short Bowel Syndrome
  • 5.1.4. Challenges
    • 5.1.4.1. Limited Initial Diagnostic and Availability of Advanced Option
• 5.2. Market Trends
• 5.3. Cumulative Impact of COVID-19
• 5.4. Cumulative Impact of Russia-Ukraine Conflict
• 5.5. Cumulative Impact of High Inflation
• 5.6. Porter's Five Forces Analysis
  • 5.6.1. Threat of New Entrants
  • 5.6.2. Threat of Substitutes
  • 5.6.3. Bargaining Power of Customers
  • 5.6.4. Bargaining Power of Suppliers
  • 5.6.5. Industry Rivalry
• 5.7. Value Chain & Critical Path Analysis
• 5.8. Regulatory Framework
• 5.9. Client Customization

6. Short Bowel Syndrome Market, by Drug Class

• 6.1. Introduction
• 6.2. GLP-2
• 6.3. Glutamine
• 6.4. Growth Hormone

7. Short Bowel Syndrome Market, by Distribution Channel

• 7.1. Introduction
• 7.2. Hospital Pharmacies
• 7.3. Online Sales
• 7.4. Retail Pharmacies

8. Americas Short Bowel Syndrome Market

• 8.1. Introduction
• 8.2. Argentina
• 8.3. Brazil
• 8.4. Canada
• 8.5. Mexico
• 8.6. United States

9. Asia-Pacific Short Bowel Syndrome Market

• 9.1. Introduction
• 9.2. Australia
• 9.3. China
• 9.4. India
• 9.5. Indonesia
• 9.6. Japan
• 9.7. Malaysia
• 9.8. Philippines
• 9.9. Singapore
• 9.10. South Korea
• 9.11. Taiwan
• 9.12. Thailand
• 9.13. Vietnam

10. Europe, Middle East & Africa Short Bowel Syndrome Market

• 10.1. Introduction
• 10.2. Denmark
• 10.3. Egypt
• 10.4. Finland
• 10.5. France
• 10.6. Germany
• 10.7. Israel
• 10.8. Italy
• 10.9. Netherlands
• 10.10. Nigeria
• 10.11. Norway
• 10.12. Poland
• 10.13. Qatar
• 10.14. Russia
• 10.15. Saudi Arabia
• 10.16. South Africa
• 10.17. Spain
• 10.18. Sweden
• 10.19. Switzerland
• 10.20. Turkey
• 10.21. United Arab Emirates
• 10.22. United Kingdom

11. Competitive Landscape

• 11.1. FPNV Positioning Matrix
• 11.2. Market Share Analysis, By Key Player
• 11.3. Competitive Scenario Analysis, By Key Player

12. List of Company Mentioned

13. Appendix

• 13.1. Discussion Guide
• 13.2. License & Pricing

1. 9 Meters Biopharma, Inc.

2. Adocia SAS

3. Ardelyx Inc.

4. AstraZeneca PLC

5. Emmaus Life Sciences, Inc.

6. Merck KGaA

7. Nestle S.A.

8. Novartis International AG

9. OPKO Health, Inc.

10. Oxthera AB

11. Pfizer Inc.

12. PhaseBio Pharmaceuticals Inc.

13. Sancilio and Company, Inc.

14. Swedish Orphan Biovitrum AB

15. Takeda Pharmaceutical Company Limited

16. Teva Pharmaceutical Industries Ltd.

17. VectivBio AG

18. Viatris Inc.

19. Zealand Pharma A/S

LIST OF FIGURES

• FIGURE 1. SHORT BOWEL SYNDROME MARKET RESEARCH PROCESS
• FIGURE 2. SHORT BOWEL SYNDROME MARKET SIZE, 2022 VS 2030
• FIGURE 3. SHORT BOWEL SYNDROME MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2022 VS 2030 (%)
• FIGURE 5. SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2022 VS 2030 (%)
• FIGURE 6. SHORT BOWEL SYNDROME MARKET SIZE, BY REGION, 2022 VS 2030 (%)
• FIGURE 7. SHORT BOWEL SYNDROME MARKET DYNAMICS
• FIGURE 8. SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 9. SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 10. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 11. UNITED STATES SHORT BOWEL SYNDROME MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 12. ASIA-PACIFIC SHORT BOWEL SYNDROME MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 13. EUROPE, MIDDLE EAST & AFRICA SHORT BOWEL SYNDROME MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 14. SHORT BOWEL SYNDROME MARKET, FPNV POSITIONING MATRIX, 2022
• FIGURE 15. SHORT BOWEL SYNDROME MARKET SHARE, BY KEY PLAYER, 2022

LIST OF TABLES

• TABLE 1. SHORT BOWEL SYNDROME MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
• TABLE 3. SHORT BOWEL SYNDROME MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 5. SHORT BOWEL SYNDROME MARKET SIZE, BY GLP-2, BY REGION, 2018-2030 (USD MILLION)
• TABLE 6. SHORT BOWEL SYNDROME MARKET SIZE, BY GLUTAMINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 7. SHORT BOWEL SYNDROME MARKET SIZE, BY GROWTH HORMONE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 8. SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 9. SHORT BOWEL SYNDROME MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. SHORT BOWEL SYNDROME MARKET SIZE, BY ONLINE SALES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. SHORT BOWEL SYNDROME MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 13. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 14. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 15. ARGENTINA SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 16. ARGENTINA SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 17. BRAZIL SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 18. BRAZIL SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 19. CANADA SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 20. CANADA SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 21. MEXICO SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 22. MEXICO SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 23. UNITED STATES SHORT BOWEL SYNDROME MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 24. UNITED STATES SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 25. UNITED STATES SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 26. ASIA-PACIFIC SHORT BOWEL SYNDROME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 27. ASIA-PACIFIC SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 28. ASIA-PACIFIC SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 29. AUSTRALIA SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 30. AUSTRALIA SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 31. CHINA SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 32. CHINA SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 33. INDIA SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 34. INDIA SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 35. INDONESIA SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 36. INDONESIA SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 37. JAPAN SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 38. JAPAN SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 39. MALAYSIA SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 40. MALAYSIA SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 41. PHILIPPINES SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 42. PHILIPPINES SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 43. SINGAPORE SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 44. SINGAPORE SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 45. SOUTH KOREA SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 46. SOUTH KOREA SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 47. TAIWAN SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 48. TAIWAN SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 49. THAILAND SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 50. THAILAND SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 51. VIETNAM SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 52. VIETNAM SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 53. EUROPE, MIDDLE EAST & AFRICA SHORT BOWEL SYNDROME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 54. EUROPE, MIDDLE EAST & AFRICA SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 55. EUROPE, MIDDLE EAST & AFRICA SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 56. DENMARK SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 57. DENMARK SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 58. EGYPT SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 59. EGYPT SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 60. FINLAND SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 61. FINLAND SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 62. FRANCE SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 63. FRANCE SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 64. GERMANY SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 65. GERMANY SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 66. ISRAEL SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 67. ISRAEL SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 68. ITALY SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 69. ITALY SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 70. NETHERLANDS SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 71. NETHERLANDS SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 72. NIGERIA SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 73. NIGERIA SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 74. NORWAY SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 75. NORWAY SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 76. POLAND SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 77. POLAND SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 78. QATAR SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 79. QATAR SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 80. RUSSIA SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 81. RUSSIA SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 82. SAUDI ARABIA SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 83. SAUDI ARABIA SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 84. SOUTH AFRICA SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 85. SOUTH AFRICA SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 86. SPAIN SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 87. SPAIN SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 88. SWEDEN SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 89. SWEDEN SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 90. SWITZERLAND SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 91. SWITZERLAND SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 92. TURKEY SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 93. TURKEY SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 94. UNITED ARAB EMIRATES SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 95. UNITED ARAB EMIRATES SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 96. UNITED KINGDOM SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 97. UNITED KINGDOM SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 98. SHORT BOWEL SYNDROME MARKET, FPNV POSITIONING MATRIX, 2022
• TABLE 99. SHORT BOWEL SYNDROME MARKET SHARE, BY KEY PLAYER, 2022
• TABLE 100. SHORT BOWEL SYNDROME MARKET LICENSE & PRICING